These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36162609)

  • 21. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Critical attributes of transdermal drug delivery system (TDDS)--a generic product development review.
    Ruby PK; Pathak SM; Aggarwal D
    Drug Dev Ind Pharm; 2014 Nov; 40(11):1421-8. PubMed ID: 24467407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro Approaches to Support Bioequivalence and Substitutability of Generic Proton Pump Inhibitors via Nasogastric Tube Administration.
    Ren P; Cui M; Anand O; Xia L; Zhao ZJ; Sun D; Sharp T; Conner DP; Peters J; Jiang W; Stier E; Jiang X
    AAPS J; 2017 Nov; 19(6):1593-1599. PubMed ID: 28879628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of Drug Properties and Formulation on In Vitro Drug Release and Biowaiver Regulation of Oral Extended Release Dosage Forms.
    Lin Z; Zhou D; Hoag S; Qiu Y
    AAPS J; 2016 Mar; 18(2):333-45. PubMed ID: 26769249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioequivalence Study Methods with Pharmacokinetic Endpoints for Topical Ophthalmic Corticosteroid Suspensions and Effects of Subject Demographics.
    Harigaya Y; Jiang X; Zhang H; Chandaroy P; Stier EM; Pan Y
    Pharm Res; 2018 Nov; 36(1):13. PubMed ID: 30443681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A generic drug primer: regulatory aspects and scientific concepts.
    Henderson JD; White GL
    Mil Med; 1998 Apr; 163(4):193-7. PubMed ID: 9575760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on the advances and challenges in bioequivalence testing methods for complex topical generic products.
    Alomari N; Alhussaini W
    Front Pharmacol; 2024; 15():1330712. PubMed ID: 38389924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
    Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
    Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A science based approach to topical drug classification system (TCS).
    Shah VP; Yacobi A; Rădulescu FŞ; Miron DS; Lane ME
    Int J Pharm; 2015 Aug; 491(1-2):21-5. PubMed ID: 26070249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan.
    Kuribayashi R; Takishita T; Mikami K
    J Pharm Sci; 2016 Aug; 105(8):2270-7. PubMed ID: 27372551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Therapeutic Equivalence for the Follow-On Version of Intravenously Administered Non-Biological Complex Drugs.
    Sun Z; Jiang J; Chen X
    Clin Pharmacokinet; 2020 Aug; 59(8):995-1004. PubMed ID: 32328977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
    Privitera MD; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Berg M
    Lancet Neurol; 2016 Apr; 15(4):365-72. PubMed ID: 26875743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical bioequivalence: Experimental and regulatory considerations following formulation complexity.
    Miranda M; Veloso C; Brown M; C Pais AAC; Cardoso C; Vitorino C
    Int J Pharm; 2022 May; 620():121705. PubMed ID: 35358644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.
    Li Z; Fang L; Jiang W; Kim MJ; Zhao L
    Curr Neurol Neurosci Rep; 2017 Sep; 17(11):82. PubMed ID: 28929357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics-Based Approaches for Bioequivalence Evaluation of Topical Dermatological Drug Products.
    Raney SG; Franz TJ; Lehman PA; Lionberger R; Chen ML
    Clin Pharmacokinet; 2015 Nov; 54(11):1095-106. PubMed ID: 26063051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the bioavailability and bioequivalence of generic medications.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):13-6. PubMed ID: 20102127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. International harmonization of bioequivalence studies and issues shared in common.
    Nakai K; Fujita M; Ogata H
    Yakugaku Zasshi; 2000 Nov; 120(11):1193-200. PubMed ID: 11190204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of Quantitative Comparative Approaches to Support Complex Generic Drug Development.
    Gong Y; Barretto FX; Tsong Y; Mousa Y; Ren K; Kozak D; Shen M; Hu M; Zhao L
    AAPS J; 2024 Jan; 26(1):15. PubMed ID: 38267593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioequivalence of generic thioridazine drug products--the FDA viewpoint.
    Hamrell MR; Martinez MN; Dighe SV; Parkman PD
    Drug Intell Clin Pharm; 1987 Apr; 21(4):362-72. PubMed ID: 3569040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.